«We now need to find out what other genes FOXM1 is activating to drive
meningioma growth, and block those targets with clinical therapies,» Raleigh said.
Raleigh's team found that a gene named FOXM1 was at the heart of aggressive
meningioma growth, and a signpost of subsequently poor clinical outcomes, including death.